.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
QuintilesIMS
Moodys
Chubb
Novartis
AstraZeneca
Deloitte
Healthtrust
Federal Trade Commission
Queensland Health

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,867,996

« Back to Dashboard

Which drugs does patent 7,867,996 protect, and when does it expire?


Patent 7,867,996 protects CORLANOR and is included in one NDA.

This patent has forty-five patent family members in forty countries.

Summary for Patent: 7,867,996

Title:.gamma.-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Abstract: A .gamma.-Crystalline form of ivabradine hydrochloride of formula (I): ##STR00001## characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Inventor(s): Horvath; Stephane (La Chapelle-Saint-Mesmin, FR), Auguste; Marie-Noelle (Orleans, FR), Damien; Gerard (Meung-sur-Loire, FR)
Assignee: Les Laboratories Servier (Suresnes Cedex, FR)
Application Number:12/583,885
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Amgen Inc
CORLANOR
ivabradine hydrochloride
TABLET;ORAL206143-001Apr 15, 2015RXYesNo► Subscribe► SubscribeYY A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
Amgen Inc
CORLANOR
ivabradine hydrochloride
TABLET;ORAL206143-002Apr 15, 2015RXYesYes► Subscribe► SubscribeYY A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,867,996

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France05 01989Feb 28, 2005

Non-Orange Book Patents for Patent: 7,867,996

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,361,650.gamma.-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,867,996

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Colombia5770097► Subscribe
Costa Rica8249► Subscribe
Cuba20060037► Subscribe
Cuba23616► Subscribe
Cyprus1109010► Subscribe
Germany602006001312► Subscribe
Denmark1707562► Subscribe
Eurasian Patent Organization200600320► Subscribe
Eurasian Patent Organization008465► Subscribe
European Patent Office1707562► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
QuintilesIMS
Covington
Queensland Health
Chinese Patent Office
McKinsey
US Department of Justice
Merck
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot